Associations of Endothelial-Related lncRNAs with Early-Onset STEMI: A Case-Control Study.

IF 2.5 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiovascular Translational Research Pub Date : 2026-02-27 DOI:10.1007/s12265-026-10745-z

Elham Madandar, Yasaman Zarinfar, Mohammad Hassan Namazi, Nasim Sohrabifar, Mohammad Javad Namazi, Vahid Eslami, Isa Khaheshi

{"title":"Associations of Endothelial-Related lncRNAs with Early-Onset STEMI: A Case-Control Study.","authors":"Elham Madandar, Yasaman Zarinfar, Mohammad Hassan Namazi, Nasim Sohrabifar, Mohammad Javad Namazi, Vahid Eslami, Isa Khaheshi","doi":"10.1007/s12265-026-10745-z","DOIUrl":null,"url":null,"abstract":"<p><p>Early-onset ST-segment elevation myocardial infarction (STEMI) in individuals under 50 is an increasing concern. Identifying new biomarkers could improve early diagnosis and intervention. In this case-control study, we investigated endothelial-related long non-coding RNAs (lncRNAs) MANTIS, NORAD, RNCR3, and SENCR as potential diagnostic markers. Blood samples from 200 young STEMI patients and 200 age-matched controls were analyzed using real-time PCR to evaluate lncRNA expression. NORAD and MANTIS levels were significantly reduced in STEMI patients (p < 0.001). MANTIS displayed the strongest association (AUC = 0.92), while NORAD demonstrated a moderate association (AUC = 0.68). SENCR and RNCR3 showed no significant differences between groups. The downregulation of MANTIS and NORAD suggests their potential roles as biomarkers in early-onset STEMI. MANTIS, in particular, may enhance risk stratification and treatment. Further research is warranted to validate these findings in broader populations.</p>","PeriodicalId":15224,"journal":{"name":"Journal of Cardiovascular Translational Research","volume":"19 1","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular Translational Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12265-026-10745-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Early-onset ST-segment elevation myocardial infarction (STEMI) in individuals under 50 is an increasing concern. Identifying new biomarkers could improve early diagnosis and intervention. In this case-control study, we investigated endothelial-related long non-coding RNAs (lncRNAs) MANTIS, NORAD, RNCR3, and SENCR as potential diagnostic markers. Blood samples from 200 young STEMI patients and 200 age-matched controls were analyzed using real-time PCR to evaluate lncRNA expression. NORAD and MANTIS levels were significantly reduced in STEMI patients (p < 0.001). MANTIS displayed the strongest association (AUC = 0.92), while NORAD demonstrated a moderate association (AUC = 0.68). SENCR and RNCR3 showed no significant differences between groups. The downregulation of MANTIS and NORAD suggests their potential roles as biomarkers in early-onset STEMI. MANTIS, in particular, may enhance risk stratification and treatment. Further research is warranted to validate these findings in broader populations.

查看原文本刊更多论文

内皮相关lncrna与早发性STEMI的关联：一项病例对照研究

早发性st段抬高型心肌梗死（STEMI）在50岁以下的个体中越来越受到关注。识别新的生物标志物可以改善早期诊断和干预。在这项病例对照研究中，我们研究了内皮相关的长链非编码rna (lncRNAs) MANTIS、NORAD、RNCR3和SENCR作为潜在的诊断标志物。使用实时荧光定量PCR技术对200名年轻STEMI患者和200名年龄匹配的对照组的血液样本进行分析，以评估lncRNA的表达。STEMI患者的NORAD和MANTIS水平显著降低(p

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cardiovascular Translational Research CARDIAC & CARDIOVASCULAR SYSTEMS-MEDICINE, RESEARCH & EXPERIMENTAL

CiteScore

6.10

自引率

2.90%

发文量

148

审稿时长

6-12 weeks

期刊介绍： Journal of Cardiovascular Translational Research (JCTR) is a premier journal in cardiovascular translational research. JCTR is the journal of choice for authors seeking the broadest audience for emerging technologies, therapies and diagnostics, pre-clinical research, and first-in-man clinical trials. JCTR''s intent is to provide a forum for critical evaluation of the novel cardiovascular science, to showcase important and clinically relevant aspects of the new research, as well as to discuss the impediments that may need to be overcome during the translation to patient care.